# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
BofA Securities upgraded Fulcrum Therapeutics ahead of its phase 3 losmapimod results for Facioscapulohumeral muscular dystroph...
B of A Securities analyst Tazeen Ahmad upgrades Fulcrum Therapeutics (NASDAQ:FULC) from Underperform to Neutral and raises t...
HC Wainwright & Co. analyst Andrew Fein reiterates Fulcrum Therapeutics (NASDAQ:FULC) with a Buy and maintains $17 price...
Fulcrum Therapeutics (NASDAQ:FULC) reported quarterly earnings of $0.87 per share his is a 328.95 percent increase over losses ...
Cantor Fitzgerald analyst Kristen Kluska reiterates Fulcrum Therapeutics (NASDAQ:FULC) with a Overweight and maintains $23 p...
Cantor Fitzgerald analyst Kristen Kluska initiates coverage on Fulcrum Therapeutics (NASDAQ:FULC) with a Overweight rating a...